Asahi Kasei Acquires Aicuris to Bolster Infectious Disease Portfolio
Event summary
- Asahi Kasei completed the acquisition of Aicuris Anti-infective Cures AG on April 20, 2026.
- Aicuris adds three antiviral assets, including Prevymis®, pritelivir, and AIC468, to Asahi Kasei’s portfolio.
- Pritelivir’s FDA New Drug Application has a PDUFA target date in Q4 2026, with projected peak revenue exceeding $400 million in the mid-to-late 2030s.
- Aicuris revenue is expected to reach $500 million by 2030, excluding AIC468.
- The acquisition will contribute positively to Asahi Kasei’s operating income from fiscal 2028 onward.
The big picture
Asahi Kasei’s acquisition of Aicuris aligns with its strategic focus on pharmaceuticals as a priority growth area. The deal strengthens its position in infectious diseases, an area with sustained demand and high unmet need. By leveraging Veloxis Pharmaceuticals’ expertise in transplant medicine, Asahi Kasei aims to accelerate the development and commercialization of Aicuris’s portfolio, addressing critical gaps in treating immunocompromised patients.
What we're watching
- Regulatory Approval
- The pace at which pritelivir secures FDA approval and its market penetration among immunocompromised patients.
- Revenue Integration
- How Asahi Kasei integrates Aicuris’s assets into its global development and commercialization platform.
- Pipeline Development
- The progress of AIC468 through clinical trials and its potential market impact in treating BK virus infection.
Related topics